Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates, has made advancements on its work on a proprietary yeast strain for the production of Tetrahydrocannabinol (“THC”); the company also announced plans to commercially launch the product in the highly regulated, legal Canadian market. Willow’s Canadian-based R&D (“R&D”) team has developed a proprietary yeast strain along with a process to produce THC; the company is eyeing a pilot scale run by the end of 2021. Willow is operating under the believe that a significant number of consumer product manufacturers are looking for a consistent, high-purity, odorless, flavorless THC ingredient, which is exactly what it is producing. Willow expects the product to be used in the 2.0 market, which includes vapes, edibles, beverages, concentrates and topicals, and has been identified as a multibillion-dollar industry. Willow also announced that it has found a development partner for product isolation, purification and scale up to pilot; in addition, the company is talking with potential manufacturing companies. “We are excited to announce our proprietary THC yeast biosynthesis production process for launch in the Canadian market,” said Willow president and CEO Trevor Peters in the press release. “Our platform technology enables us to produce a variety of cannabinoids and leverage our previous work on CBG. From conversations with prospective customers in Canada , we believe that there is significant demand for consistent, high-purity THC. The flavorless, odorless attributes of our finished product make it suitable as a core ingredient for the cannabis 2.0 market in Canada . There is also strong demand for a more sustainable and environmentally friendly way to produce THC. Our manufacturing process is 50 to 500 times more efficient than indoor cultivation and is the next evolution of sustainable cannabinoid manufacturing.”
To view the full press release, visit https://ibn.fm/EIfBW
About Willow Biosciences Inc.
Willow is a Canadian biotechnology company based in Vancouver, British Columbia, which produces high-purity, plant-derived compounds that provide building blocks for the global pharmaceutical, health and wellness, and consumer packaged goods industries. Willow’s current focus is on the production of cannabinoids for the treatment for pain, anxiety, obesity and brain disorders, among other significant indications. Willow’s science team has a proven track record of developing manufacturing technologies for high-purity compounds in pain and cancer treatments. Willow’s manufacturing process creates a consistent, scalable and sustainable product that allows for the discovery and development of new life-changing drugs. For more information about the company, visit www.WillowBio.com.
NOTE TO INVESTORS: The latest news and updates relating to WLLW are available in the company’s newsroom at http://ibn.fm/WLLW
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment